Corbus Pharmaceuticals Holdings (CRBP) executive compensation, 2026 proxy

Yuval Cohen, Chief Executive Officer, was paid $3.8M in 2025, down 12% from $4.2M the year before.

Filed
April 2, 2026
Annual meeting
May 13, 2026
Pay year
2025
Named executives
3
CEO total pay
$3.8M-12% vs prior year
CEO pay in equity
72%$2.7M in awards
CEO Target Bonus
60%Of base salary
CFO Target Bonus
40%Of base salary
CMO Target Bonus
40%Of base salary

How Cohen was paid

$3.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary17%Bonus10%Stock awards18%Option awards54%All other compensation1%

Named executive officers

ExecutiveTotal
Yuval CohenChief Executive Officer$3,750,125
Sean MoranChief Financial Officer$1,789,423
Dominic SmethurstChief Medical Officer$1,800,142

What changed and why

  • $3.8MChief Executive Officer Yuval Cohen total compensation decreased to $3,750,125 in 2025 from $4,245,438 in 2024.
  • $667KStock awards for the chief executive officer decreased to $666,699 in 2025.
  • $2MOption awards for the chief executive officer were $2,039,294 in 2025.
  • $647KChief executive officer base salary increased to $646,566 in 2025.
  • $1.8MChief financial officer total compensation decreased to $1,789,423 in 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.